Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Trial Profile

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as unable to get materials from GE, study not proceeding and never opened to accrual
    • 05 Sep 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018.
    • 20 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top